April 27, 2017 09:48 AM EDT

Tesaro gets its PD-1 registration study started, hunting accelerated OK; Ultragenyx hustles into PhIII

Shehla Shakoor

Managing Director

→ Tesaro $TSRO has launched a registration study for its PD-1 drug TSR-042, which was developed in a collaboration with AnaptysBio. The biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tesaro gets its PD-1 registration study started, hunting accelerated OK; Ultragenyx hustles into PhIII

Shehla Shakoor

Managing Director

Sign up to read this article for free.

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Tesaro gets its PD-1 reg­is­tra­tion study start­ed, hunt­ing ac­cel­er­at­ed OK; Ul­tragenyx hus­tles in­to PhI­II

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

Tesaro gets its PD-1 registration study started, hunting accelerated OK; Ultragenyx hustles into PhIII

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology